|
|
|
Insider
Information: |
Nashat Amir |
Relationship: |
Director, 10% Owner |
City: |
San Diego |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
8 |
|
Direct
Shares |
51,211 |
|
Indirect Shares
|
2,932,442 |
|
|
Direct
Value |
$338,447 |
|
|
Indirect Value
|
$43,278,680 |
|
|
Total
Shares |
2,983,653 |
|
|
Total
Value |
$43,617,127 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Receptos, Inc. |
RCPT |
Director |
2013-05-14 |
0 |
2014-05-27 |
274 |
Premium* |
|
Fate Therapeutics Inc |
FATE |
Director |
2013-10-04 |
0 |
2019-08-01 |
11,034 |
Premium* |
|
aTyr Pharma Inc |
LIFE |
Former 10% Owner, Dire... |
2015-05-12 |
12,572 |
2015-05-12 |
17,638 |
Premium* |
|
Cartesian Therapeutics, Inc |
RNAC |
Director |
|
0 |
2019-01-25 |
2,676,234 |
Premium* |
|
Syros Pharmaceuticals, Inc. |
SYRS |
Director, 10% Owner |
2016-07-06 |
0 |
2016-07-06 |
48,320 |
Premium* |
|
Scholar Rock Holding Corp |
SRRK |
|
2024-05-09 |
38,639 |
2024-05-09 |
0 |
Premium* |
|
Morphic Holding, Inc. |
MORF |
|
2024-08-16 |
0 |
2024-08-16 |
0 |
Premium* |
|
Metacrine, Inc. |
MTCR |
Director, 10% Owner |
2020-09-18 |
0 |
2020-09-18 |
178,942 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
76 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
LIFE |
aTyr Pharma Inc |
Director |
|
2015-05-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,572 |
|
- |
|
RNAC |
Cartesian Therapeutics, I... |
Director |
|
2016-06-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
40,742 |
|
- |
|
RCPT |
Receptos, Inc. |
Director |
|
2013-05-14 |
4 |
OE |
$7.73 |
$8,005,165 |
I/I |
1,035,597 |
1,035,597 |
0 |
- |
|
RCPT |
Receptos, Inc. |
Director |
|
2013-05-14 |
4 |
B |
$14.00 |
$2,118,802 |
I/I |
151,343 |
1,186,940 |
2.1 |
- |
|
FATE |
Fate Therapeutics Inc |
Director |
|
2013-10-04 |
4 |
A |
$0.00 |
$0 |
I/I |
1,511,407 |
1,511,407 |
0 |
- |
|
FATE |
Fate Therapeutics Inc |
Director |
|
2013-10-04 |
4 |
A |
$6.00 |
$770,676 |
I/I |
128,446 |
1,639,853 |
0 |
- |
|
FATE |
Fate Therapeutics Inc |
Director |
|
2013-10-04 |
4 |
B |
$6.00 |
$4,999,998 |
I/I |
833,333 |
2,473,186 |
2.25 |
- |
|
RCPT |
Receptos, Inc. |
Director |
|
2013-11-14 |
4 |
S |
$25.00 |
$3,852,225 |
I/I |
(154,089) |
1,032,001 |
0 |
- |
|
RCPT |
Receptos, Inc. |
Director |
|
2013-11-15 |
4 |
S |
$24.54 |
$373,646 |
I/I |
(15,226) |
1,016,775 |
0 |
- |
|
RCPT |
Receptos, Inc. |
Director |
|
2013-11-20 |
4 |
S |
$22.77 |
$698,697 |
I/I |
(30,685) |
56,237 |
0 |
- |
|
RCPT |
Receptos, Inc. |
Director |
|
2013-12-06 |
4 |
S |
$26.69 |
$4,538,860 |
I/I |
(170,000) |
46,851 |
0 |
- |
|
RCPT |
Receptos, Inc. |
Director |
|
2014-05-27 |
4 |
A |
$0.00 |
$0 |
I/I |
3,827 |
3,827 |
0 |
- |
|
RCPT |
Receptos, Inc. |
Director |
|
2014-05-27 |
4 |
D |
$0.00 |
$0 |
I/I |
(383,100) |
386,989 |
0 |
- |
|
LIFE |
aTyr Pharma Inc |
Former 10% Owner |
|
2015-05-12 |
4 |
A |
$0.00 |
$0 |
I/I |
1,827,992 |
17,638 |
0 |
- |
|
RNAC |
Cartesian Therapeutics, I... |
Director |
|
2016-06-27 |
4 |
A |
$0.00 |
$0 |
I/I |
1,712,695 |
1,691,963 |
0 |
- |
|
RNAC |
Cartesian Therapeutics, I... |
Director |
|
2016-06-27 |
4 |
B |
$14.00 |
$2,100,000 |
I/I |
150,000 |
1,836,703 |
2.25 |
- |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2016-07-06 |
4 |
B |
$12.50 |
$5,000,000 |
I/I |
400,000 |
48,320 |
2.25 |
- |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2016-07-06 |
4 |
A |
$0.00 |
$0 |
I/I |
1,186,653 |
22,167 |
0 |
- |
|
RNAC |
Cartesian Therapeutics, I... |
Director |
|
2017-09-20 |
4 |
S |
$20.03 |
$853,389 |
I/I |
(42,610) |
1,795,587 |
0 |
- |
|
RNAC |
Cartesian Therapeutics, I... |
Director |
|
2017-09-21 |
4 |
S |
$19.86 |
$2,076,826 |
I/I |
(104,577) |
1,694,676 |
0 |
- |
|
RNAC |
Cartesian Therapeutics, I... |
Director |
|
2017-09-22 |
4 |
S |
$19.26 |
$809,781 |
I/I |
(42,036) |
1,654,114 |
0 |
- |
|
RNAC |
Cartesian Therapeutics, I... |
Director |
|
2017-09-25 |
4 |
S |
$18.99 |
$705,883 |
I/I |
(37,175) |
1,618,242 |
0 |
- |
|
RNAC |
Cartesian Therapeutics, I... |
Director |
|
2017-09-26 |
4 |
S |
$18.91 |
$1,328,079 |
I/I |
(70,226) |
1,550,478 |
0 |
- |
|
SRRK |
Scholar Rock Holding Corp |
Director |
|
2018-05-29 |
4 |
B |
$14.00 |
$1,999,998 |
I/I |
142,857 |
156,395 |
2.25 |
- |
|
SRRK |
Scholar Rock Holding Corp |
Director |
|
2018-05-29 |
4 |
A |
$0.00 |
$0 |
I/I |
2,689,849 |
148,508 |
0 |
- |
|
76 Records found
|
|
Page 1 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|